Cargando…

Results from a Prospective, Open-Label, Phase 4 Pilot Study of Repository Corticotropin Injection for Moderate and Severe Dry Eye Disease

INTRODUCTION: There is a substantial unmet need for effective therapies to treat patients with refractory dry eye disease (DED). The goal of this open-label pilot study was to investigate the efficacy and safety of repository corticotropin injection (RCI; Acthar® Gel; Mallinckrodt Pharmaceuticals) i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toyos, Melissa, Toyos, Rolando, Jodoin, Barbara, Bunch, Ryan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114278/ https://www.ncbi.nlm.nih.gov/pubmed/35460497 http://dx.doi.org/10.1007/s40123-022-00501-2

Ejemplares similares

Intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction: A randomized controlled study
por: Toyos, Rolando, et al.
Publicado: (2022)

Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies
por: Patel, Aarat, et al.
Publicado: (2016)

Treatment of fibrillary glomerulonephritis with use of repository corticotropin injections
por: Maroz, Natallia, et al.
Publicado: (2018)

Repository Corticotropin Injection (Acthar(®) Gel) for Refractory Severe Noninfectious Keratitis: Efficacy and Safety from a Phase 4, Multicenter, Open-Label Study
por: Wirta, David, et al.
Publicado: (2021)

Repository corticotropin injection in patients with rheumatoid arthritis resistant to biologic therapies
por: Fischer, Peter A, et al.
Publicado: (2018)

Treatment of Noninfectious Retinal Vasculitis Using Subcutaneous Repository Corticotropin Injection
por: Anesi, Stephen D., et al.
Publicado: (2021)

Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review
por: Mirsaeidi, Mehdi, et al.
Publicado: (2022)

Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials
por: Shen Lee, Bridgitte, et al.
Publicado: (2022)

Repository corticotropin for Chronic Pulmonary Sarcoidosis
por: Baughman, Robert P., et al.
Publicado: (2017)

Repository corticotropin injection in patients with refractory psoriatic arthritis: a case series
por: Brown, Alan N
Publicado: (2016)

Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis
por: Hunter, Samuel F, et al.
Publicado: (2021)

Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis
por: Busch, Howard, et al.
Publicado: (2022)

A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus
por: Askanase, Anca D., et al.
Publicado: (2022)

Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study
por: Furie, Richard, et al.
Publicado: (2016)

Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records
por: Chopra, Ishveen, et al.
Publicado: (2019)

Repository Corticotropin Injections Promote Clinical Remission and Regulatory T Cell Expansion in Membranous Nephropathy
por: Hartzell, Susan, et al.
Publicado: (2021)

Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial
por: Schechter, Barry A, et al.
Publicado: (2022)

Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification
por: Toyos, Melissa M.
Publicado: (2019)

Continuous Wave Fractional CO(2) Laser for the Treatment of Upper Eyelid Dermatochalasis and Periorbital Rejuvenation
por: Toyos, Melissa Morrison
Publicado: (2017)

A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
por: Tauber, Joseph, et al.
Publicado: (2018)

H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes
por: Kutz, Christen
Publicado: (2016)

Pharmacodynamics and tolerability of repository corticotropin injection in healthy human subjects: A comparison with intravenous methylprednisolone
por: Lal, Ritu, et al.
Publicado: (2015)

Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis
por: Ho-Mahler, Nancy, et al.
Publicado: (2020)

Understanding Predictors of Response to Repository Corticotropin Injection Treatment Among Patients With Advanced Symptomatic Sarcoidosis
por: Bindra, Jas, et al.
Publicado: (2022)

Cost-Effectiveness of Repository Corticotropin Injection versus Standard of Care for the Treatment of Active Rheumatoid Arthritis
por: Bindra, Jas, et al.
Publicado: (2021)

Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms
por: Gold, Laura S, et al.
Publicado: (2019)

Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab
por: Knight, Tyler, et al.
Publicado: (2017)

A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse
por: Kaplan, Jeffrey, et al.
Publicado: (2020)

Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis
por: Fleischmann, Roy, et al.
Publicado: (2022)

Industry Payments to Physician Specialists Who Prescribe Repository Corticotropin
por: Hartung, Daniel M., et al.
Publicado: (2018)

Effect of Oral Re-esterified Omega-3 Nutritional Supplementation on Dry Eyes
por: Epitropoulos, Alice T., et al.
Publicado: (2016)

Retrospective Medical Record Review to Describe Use of Repository Corticotropin Injection Among Patients with Uveitis in the United States
por: Nelson, Winnie W., et al.
Publicado: (2019)

Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial
por: Fleischmann, Roy, et al.
Publicado: (2020)

Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis
por: Rice, J. Bradford, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Repository Corticotropin Injection Compared With Synthetic ACTH(1‐24) Depot and Methylprednisolone in Healthy Subjects
por: Poola, Nagaraju, et al.
Publicado: (2021)

Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review
por: Girman, Cynthia, et al.
Publicado: (2022)

A Randomized Prospective Trial Comparing Repository Corticotropin Injection and Intravenous Methylprednisolone for Neuroprotection in Acute Optic Neuritis
por: Bennett, Jeffrey L., et al.
Publicado: (2023)

Repository corticotropin injection attenuates collagen-induced arthritic joint structural damage and has enhanced effects in combination with etanercept
por: Decker, Dima A., et al.
Publicado: (2020)

Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model
por: Hayes, Kyle, et al.
Publicado: (2020)

Cost per response analysis of repository corticotropin injection versus other alternative treatments for acute exacerbations of multiple sclerosis
por: Wan, George J, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mkplkg8bb7rsv07l7q2ugurcsr